Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer in the world (1) . HNSCC impairs oral functionality and aesthetics, resulting in a low quality of life. Tumour stage, lymph node metastasis and invasive pattern contribute to poor outcomes (2, 3) .
Angiogenesis is the formation of new blood vessels and is important for tumour progression and metastasis (4) . Vasohibin-1 (VASH1) is a negative feedback regulator of angiogenesis that is induced by vascular endothelial growth factor (VEGF) and fibroblast growth factor-2 (FGF2) in activated endothelial cells (5, 6) . Previous studies have shown that VASH1 expression in tumour blood vessels is associated with VEGF and FGF2 expression in tumour cells (7) . VASH1 expression in tumour blood vessels is associated with the clinical outcomes of various types of cancers, such as breast cancer, hepatocellular carcinoma, non-small cell lung cancer, prostate cancer, renal cell carcinoma and upper urinary tract urothelial carcinoma (8) (9) (10) (11) (12) (13) (14) (15) . Conversely, VASH1 expression in tumour cells, but not in tumour blood vessels, is associated with clinical outcomes of colorectal cancer (16) .
Here we examined VASH1 expression in HNSCC specimens by immunohistochemistry and investigated whether VASH1 expression was related to clinicopathological factors and prognosis.
Materials and Methods
Study population. We examined 61 patients with HNSCC who underwent surgical resection at Hokkaido University Hospital, Sapporo, Japan from 1995 to 2008. None of the patients had undergone radiation therapy or chemotherapy preoperatively or postoperatively. Patients were followed-up postoperatively as follows: physical examination every month for the first year, every 2 months for the following year and every 3-6 months for the subsequent years, with CT every 3 months for the first 2 years postoperatively and when relapse was suspected. The follow-up period was 14-194 months (median=71 months). This study was approved by the Ethics Committee of Hokkaido University. Patient characteristics are shown in Table I .
Clinical data were retrieved from medical charts. Clinicopathological factors included age, sex, tumour location, tumour stage, T factor and lymph node metastasis. Stage categories were based on TNM Classification of Malignant Tumours by the Union for International Cancer Control (17) .
The normal adjacent tissue apart from the tumour tissue was evaluated as a non-neoplastic counterpart of HNSCC.
Immunohistochemistry. Tissue samples were fixed in 10% formalin, embedded in paraffin and cut into 4-μm-thick sections. We performed immunohistochemical staining for VASH1, cluster of differentiation 34 (CD34), pan-cytokeratin with AE1/AE3 as an epithelial marker and for Ki67 as a proliferation marker. Tissue sections were deparaffinized in xylene (Sigma-Aldrich, Tokyo, Japan) and hydrated through a graded alcohol series then finally in distilled water. For antigen retrieval, the tissue sections were heated in a water-bath at 95˚C for 30 min in Histofine antigen retrieval solution (pH 9.0; Nichirei Corporation, Tokyo, Japan) diluted at 1:10. Endogenous peroxidase activity was blocked by incubation in 0.5% hydrogen peroxidase (Sigma-Aldrich) for 10 min at room temperature. Then the sections were incubated with a blocking solution of 5% goat serum in tris-buffered saline (TBS) for 30 min.
The processed sections were stained overnight at 4˚C with primary monoclonal antibodies. The primary antibodies used were as follows: mouse monoclonal anti-human VASH1 (diluted at 1:1000), rabbit polyclonal anti-human CD34 (EP373Y, diluted at 1:500; Abcam, Cambridge, MA, USA), mouse monoclonal antihuman cytokeratin, clone AE1/AE3 (IR053, diluted at 1:20; Dako, Tokyo, Japan) and mouse anti-human Ki-67 (M7240, diluted at 1:500; Dako). The specificity of this antibody to VASH1 was documented in a previous study (5) . After washing with TBS, the sections were incubated with secondary antibodies for 60 min at room temperature. 3,3'-Diaminobenzidine was used as the chromogen (K3468, Liquid DAB+ Substrate Chromogen System; Dako). The sections were then counterstained with hematoxylin (Wako, Osaka, Japan).
Evaluation of immunohistochemical staining. All sections were independently evaluated by two investigators. When the results of the evaluations were different, another investigator performed an evaluation for the final decision. All investigators were blinded to the clinicopathological information. To analyse VASH1 expression in the tumour, as many areas as possible were randomly selected within the tumour at low magnification (×100). The number of areas observed depended on the tumour sample size. The pixel number in the VASH1-positive area at high magnification (×200) was determined using ImageJ software (National Institutes of Health, Bethesda, MD, USA). VASH1 expression in the tumour was calculated as the ratio of the pixel number of the VASH1-positive area to that of the total area. The cut-off for VASH1 expression in the tumour was 1.1% for the analysis of disease-free survival, which was the point with the lowest p-value in a log-rank test.
Statistical analysis. The association between clinicopathological factors and VASH1 expression in the tumour was validated by chi-square tests. We also used univariate and multivariate analyses with Cox proportional hazards regression model. Disease-free survival and lymph node recurrence were estimated using the Kaplan-Meier method and analysed by the log-rank test. Differences among groups were regarded as significant when p<0.05. Statistical analyses were performed using SPSS version 18.0 (IBM Corporation, Armonk, NY, USA).
Results

VASH1 expression in HNSCC and patient characteristics.
Blood vessels in HNSCC specimens and normal adjacent tissue were CD34-positive ( Figure 1A, C, E and G). Although the normal adjacent tissue was VASH1-negative ( Figure 1B) , tumour blood vessels were VASH1-positive ( Figure 1D) ; however, some cases were VASH1-negative ( Figure 1F ). Not only tumour blood vessels but also tumour cells were VASH1-positive ( Figure 1H ). We confirmed that VASH1-positive cells, except for tumour endothelial cells, were tumour cells by immunohistochemistry for AE1/AE3 as an epithelial marker. HNSCC cells were AE1/AE3-positive, and serial sections showed that some AE1/AE3-positive tumour cells were also VASH1-positive (Figure 2A-D) . Some VASH1-positive tumour cells appeared to be Ki67-positive ( Figure 2E and F) . These results indicate that some VASH1-positive tumour cells were proliferative. Table I indicates the clinicopathological parameters of 61 patients. Among 61 cases, eight patients died (three with HNSCC, five from, other causes). Nine patients developed lymph node recurrence out of the 12 patients who experienced relapse. The mean and median duration of disease-free survival was 56.2 and 59 months, respectively.
Prognostic significance of VASH1 expression in patients with HNSCC. The cut-off for VASH1 expression in the tumour for survival analyses was 1.1%. Cases with <1.1% VASH1 expression in tumour were defined as having low VASH1 expression and the remaining cases were defined as having high VASH1 expression. Thirty-one cases had high VASH1 expression (Table I ). Univariate analysis revealed that lymph node metastasis and VASH1 expression in the tumour were significant predictors of recurrence (p=0.0457 and 0.0367, respectively). Multivariate analysis revealed that VASH1 expression in the tumour was a significant predictor of recurrence (p=0.045, hazard ratio=3.04). Multivariate analysis confirmed that high VASH1 expression in the tumour was an independent predictor of poorer disease-free survival. Table II shows the association between VASH1 expression level in the tumour and clinicopathological parameters in 61 patients with HNSCC. High VASH1 expression in the tumour was significantly associated with lymph node recurrence (p=0.018). Disease-free survival was significantly lower in cases with high VASH1 expression in the tumour (p=0.027, Figure 3 ). Sixty percent of relapses were lymph node recurrence. These results indicated that high VASH1 expression was an independent predictor of lymph node recurrence and of poorer disease-free survival of HNSCC.
Discussion
Here we revealed that HNSCC tumour and vascular endothelial cells expressed VASH1. We also found that high VASH1 expression in HNSCC was significantly associated with shorter disease-free survival and higher lymph node recurrence. Our study shows, as far as we are aware for the first time, that VASH1 is a prognostic factor for HNSCC.
Recently, associations have been reported between VASH1 expression and prognosis of patients with various types of cancer (8) (9) (10) (11) (12) (13) (14) (15) . For example, in prostate cancer and non-small cell lung cancer, VASH1 expression was associated with tumour progression, and high VASH1 expression was a negative predictor, with specific VASH1 expression in tumour-associated endothelial cells being reported (11, 12) . VASH1 expression in tumour cells has been reported in renal cell cancer and colon cancer (13, 16, 18) . Yan et al. reported a strong positive association between VASH1 and VEGFA expression and microvessel density (MVD) in colorectal cancer tissues. VASH1 expression was significantly positively associated with pathological TNM stage, tumour stromal invasion, lymph node involvement, distant metastasis and shorter survival (16) . VASH1 expression was reported in colon cancer cells and this was positively associated with tumour progression, MVD and poor prognosis (18) . In contrast to these studies on colon cancer, Zhao et al. reported that higher VASH1 expression was associated with a lower MVD and better prognosis of renal cell cancer (13 VASH1 expression in the adjacent normal tissue in the kidney, but not in the colon. There may be different types of regulation and roles of VASH1 in each organ. Our immunohistochemical analyses of HNSCC specimens confirmed VASH1 expression in tumour and endothelial cells, while no VASH1 expression was found in the normal adjacent tissue. The fact that VASH1-positive tumour cells were also positive for Ki67 suggests that these tumour cells were proliferative. The association between Ki67 and VASH1 in tumour cells has not been reported; VASH1 expression itself might promote tumour development or merely reflect VEGFA abundance in the tissue.
HNSCC negative for cervical node involvement, as diagnosed by palpation, computed tomography and 2-[ 18 F] fluoro-2-deoxy-D-glucose positron-emission tomography, may in fact have micrometastasis in the lymph node. It is estimated that the prevalence lymph node micrometastasis is 20-40% (19) . Patients with lymph node micrometastasis will likely develop lymph node metastases in a few months to several years. Therefore, biomarkers capable of predicting lymph node recurrence would be useful in determining whether cervical lymph node dissection is necessary.
Our study showed that VASH1 expression is a predictor of shorter disease-free survival, as well as highlighting an association between high VASH1 expression and lymph node recurrence. These results suggest that VASH1 expression in preoperative biopsy specimens might be a useful marker for determining treatment and follow-up strategies. A larger cohort study would clarify the importance of VASH1 expression in HNSCC tumour.
Our study showed that VASH1 is expressed in HNSCC tumour and tumour endothelial cells and that VASH1 expression is associated with poorer disease-free survival and lymph node recurrence. 
